HOME >> MEDICINE >> NEWS
Infliximab could offer long-term benefits to people with Crohns disease

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohns disease, conclude authors of a study in this weeks issue of THE LANCET.

Crohns disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous research has suggested that the drug infliximab could reduce disease symptoms in the short term; Stephen Hanauer and colleagues from the University of Chicago, USA, investigated whether treatment with infliximab every two months could be more effective in reducing the symptoms of Crohns disease in the longer term compared with a single infusion of the drug.

355 patients with severe Crohns disease from the USA, Europe, and Israel who responded within two weeks to an initial 5 mg/kg intravenous infusion of infliximab took part in the study. They were randomly assigned repeat infusions of placebo, repeat infusions of 5 mg/kg infliximab, or 10 mg/kg infliximab (after two treatments with 5mg/kg infliximab). Treatment took place at randomisation, after one month, and thereafter every two months for a year.

More than twice as many people given infliximab every two months were in remission after 30 weeks compared with patients who only received initial infliximab treatment followed by placebo. Patients given sustained infliximab responded for longer (for 38 and 54 weeks for 5mg/kg and 10mg/kg regimens, respectively) compared with patients given placebo (who only responded to treatment for an average of 19 weeks). Patients given infliximab were also more likely to discontinue use of steroids compared with those given placebo.

Stephen Hanauer comments: This study was important to demonstrate a sustained response to maintenance treatment with infliximab in Crohns disease, similar to the results with maintenance treatment for rheumatoid arthritis. After a series of inductive infusions at baseline, 2 and
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
2-May-2002


Page: 1 2

Related medicine news :

1. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
2. Novel therapy tested in mice could chase away cat allergies
3. Costs of antidepressants could have funded effective alternatives
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Blood pressure treatment could cut risk of strokes and heart attacks
6. Proteins found in urine of pregnant women could help diagnose preeclampsia
7. Three out of the four million newborn babies who die each year could be saved
8. Increasing physician volume requirement could improve mammogram accuracy, study concludes
9. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
10. Training could remove racial bias from police reactions
11. Test could improve detection of prion disease in humans

Post Your Comments:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... for Women’s Cancer announce today that Dr. Beth ... of the Claudia Cohen Research Foundation Prize for Outstanding ... the Society of Gynecologic Oncology 46th Annual Meeting on ... of the Cedars-Sinai Women’s Cancer Program at the Samuel ...
(Date:3/29/2015)... 29, 2015 Youth Villages will participate ... Oregon to assess the feasibility of implementing a Pay ... behavioral problems and their families. , Third Sector Capital ... that will be provided technical assistance throughout 2015 toward ... six other national awardees chosen by Third Sector. The ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... Take a bite of warm, gooey ... Acids tumble into the stomach, ready to break down ... lets these acids run amok, triggering a burning sensation ... More than 60 million Americans have heartburn at least ... starts, and how it can be stopped. , Heartburn ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... , March 27, 2015 Across the ... to meeting challenges in clinical development, market education, and ... regulations, the Medical Affairs function is expected to increase ... markets. According to research by benchmarking ... have a group dedicated to Medical Affairs. Among companies ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
Cached News: